Biological Testing Facility for Contraception & Reproductive Health
ID: 360583Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/360583
Timeline
    Description

    The National Institutes of Health (NIH) is announcing a funding opportunity for access to a state-of-the-art Biological Testing Facility (BTF) aimed at advancing contraceptive and reproductive health-related product development. This initiative seeks to support innovative and validated methods for fertility regulation and the development of new therapies in reproductive health, addressing a critical need for effective fertility regulation methods. While applications are not currently being solicited, potential applicants are encouraged to prepare their projects in anticipation of the opportunity, with an estimated synopsis post date of October 6, 2025, and an estimated award date of February 23, 2026. For further inquiries, interested parties can contact Dr. Leigh Allen at leigh.allen@nih.gov or by phone at 301-594-9151.

    Point(s) of Contact
    Leigh Allen, Ph.D.
    (301) 594-9151
    leigh.allen@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Development of Novel or Improved Infertility Technologies (R61/R33 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce a funding opportunity for the development of novel or improved infertility technologies through a phased R61/R33 grant mechanism. This initiative aims to support multidisciplinary research focused on creating or enhancing technologies, including drugs, devices, and clinical practices, to improve fertility outcomes, particularly in the context of assisted reproductive technologies (ART). With an estimated total program funding of $3.3 million and the expectation of awarding 11 grants, potential applicants are encouraged to prepare collaborative projects in advance of the official solicitation, which is anticipated to be published in July 2025. For further inquiries, interested parties can contact Travis Kent, PhD, at travis.kent@mail.nih.gov or call 301-435-2295.
    Development of Novel or Improved Infertility Technologies (R61/R33 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Development of Novel or Improved Infertility Technologies (R61/R33 Clinical Trial Optional)" aimed at supporting multidisciplinary research to enhance technologies for infertility treatment, particularly through Assisted Reproductive Technologies (ART). This initiative seeks to fund innovative projects that lead to the development of validated technologies, with a phased award structure allowing for up to five years of support—two years for the exploratory R61 phase (no clinical trials) and up to three years for the developmental R33 phase (clinical trials permitted). The NIH plans to allocate $3.3 million in FY 2026 to fund up to 11 R61 awards, with the potential for up to 7 projects to transition to the R33 phase. Interested applicants can find more information and application details at the provided link and should direct inquiries to grantsinfo@nih.gov, with the application deadline set for November 20, 2025.
    Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), is offering a funding opportunity titled "Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)." This initiative aims to support the development of non-hormonal contraceptives and reproductive health products by providing access to a state-of-the-art facility that offers preclinical services, including protein generation, high throughput screening, and drug metabolism studies. The program is designed to facilitate research that leads to safe and effective reproductive health therapies, with a focus on innovation and scientific merit in project proposals. Applications are open from September 3, 2023, with deadlines on October 3 and April 3 annually until 2026. Eligible applicants include various organizations such as higher education institutions, non-profits, and tribal governments. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Biomedical Technology Optimization and Dissemination Center (BTOD)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity for the Biomedical Technology Optimization and Dissemination Center (BTOD) program, aimed at optimizing late-stage biomedical technologies that have shown laboratory feasibility. The program's objective is to advance these technologies to a point of widespread use and promote their dissemination within the biomedical research community. This initiative is crucial for enhancing the application of innovative biomedical solutions, thereby contributing to advancements in health research. Interested applicants, including Indian/Native American Tribal Governments, eligible federal agencies, and community-based organizations, can reach out to Dr. Carolina Salvador Morales at carolina.salvadormorales@nih.gov or by phone at 301-480-0779 for further details. The estimated project start date is April 1, 2027, with a synopsis close date projected for May 28, 2026.
    Infertility Training Center
    Office of the Assistant Secretary for Health
    The Office of the Assistant Secretary for Health is offering a federal grant opportunity to establish an Infertility Training Center, aimed at enhancing infertility diagnostic treatments and referrals for patients at Title X-funded clinics. The center will provide training and technical assistance to Title X grantees, focusing on educating about the root causes of infertility, promoting access to holistic treatments, and improving referrals to specialists. With an estimated total program funding of $1.5 million and a single award anticipated, interested applicants, which may include any public or private nonprofit entity, should note that the application deadline is expected to close on August 15, 2025, with awards anticipated by September 30, 2025. For further inquiries, applicants can contact Amy Margolis at amy.margolis@hhs.gov or by phone at 240-453-2820.
    Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the development of Collaborative Research Facilities or Research-Resource Facilities through a federal grant opportunity titled "Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)." This initiative aims to fund the construction or modernization of shared-use biomedical research facilities that will enhance research capabilities, promote interdisciplinary collaboration, and address emerging health concerns, particularly in the areas of HIV/AIDS and other biomedical fields. With an estimated total program funding of $88 million and the expectation of awarding 12 grants, interested private institutions of higher education are encouraged to apply. Key deadlines include the estimated synopsis post date on July 28, 2025, and the application close date on January 25, 2026. For further inquiries, applicants can contact Xiang-Ning Li, MD, PhD, at xiang-ning.li@nih.gov or by phone at 301-435-1744.
    Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Planning for Product Development Strategy," aimed at supporting the development of comprehensive strategies for next-generation treatments and preventive measures for HIV and its associated complications. This grant opportunity encourages eligible applicants, including various educational institutions and community organizations, to create innovative product development plans that align with FDA guidelines, facilitating the submission of Investigational New Drug (IND) applications. With a total estimated funding of $225,000 available for individual projects, applications are due by December 5, 2026, and must adhere to specific guidelines emphasizing scientific merit and compliance. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link provided in the announcement.
    NIH Director’s Transformative Research Awards (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce the NIH Director’s Transformative Research Awards, a federal grant opportunity aimed at supporting innovative and unconventional research projects. This program encourages individual scientists or collaborative teams to propose groundbreaking research that has the potential to redefine scientific paradigms or develop transformative technologies, without the need for preliminary data or detailed experimental plans. With an estimated total funding of $8 million and the expectation of awarding seven grants, interested applicants should prepare their proposals in advance, as applications will be solicited starting June 20, 2025, with a closing date of September 3, 2025. For further inquiries, potential applicants can contact Dr. Patricia Labosky at TransformativeAwards@mail.nih.gov or by phone at 301-594-4863.
    Funding Opportunity Announcement - NIBIB Technology Development Networks
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for the NIBIB Technology Development Networks, aimed at establishing Coordinating Centers that will facilitate collaboration among scientific and engineering communities to address translational challenges in health technology development. These centers will enhance integration across various technology development projects, disseminate program advancements, and manage an Opportunity Funds program to support promising small-scale initiatives. With an estimated total program funding of $1 million and a projected award ceiling of $1 million, this cooperative agreement is expected to yield one award, with applications not currently being solicited. Interested parties are encouraged to prepare for future submissions, with key dates including an estimated synopsis post date of May 1, 2026, and an estimated award date of April 1, 2027. For further inquiries, potential applicants can contact Luisa Russell via email at luisa.russell@nih.gov.
    PHS 2025-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting eligible United States small business concerns (SBCs) to prepare applications for the PHS 2025-2 Omnibus Solicitation for Small Business Technology Transfer (STTR) Grant Applications, which includes Phase I, Phase II, Fast-Track, and Phase IIB grants. This opportunity aims to support innovative research and development projects that align with the NIH's mission, encouraging collaborations that leverage the technological expertise of small businesses in the health sector. The solicitation is contingent upon the reauthorization of the STTR program, with an estimated synopsis posting date of October 1, 2025, and a closing date of January 5, 2026. Interested applicants can reach out to the NIH SEED Office of Extramural Research at SEEDinfo@nih.gov or call 301-827-8595 for further information.